Drugs / SK10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06026397 | Aug 2023 → Feb 2024 | chemotherapy-induced toxicity | Guangzhou Zhiyi Biotechnology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SK10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06026397 ↗ |
| Known as | Inactivated Bacteroides Fragilis | “A Randomized, Double-blind, Placebo-controlled, Sequential Dose-escalation Clinical Study to Evaluate the Safety and Tolerability of SK10 Powders (Inactivated Bacteroides...” NCT06026397 ↗ |
| Route | Oral | “oral suspension of SK10 powder” NCT06026397 ↗ |